Mr. Mark Saldanha
Managing Director and CEO
Mr. Saldanha is the founder promoter of the company. Prior to Marksans, he had been associated with Glenmark Pharmaceuticals Ltd. as a Whole Time Director. He is well versed with the overall management of the company and has vast experience across the marketing, production and finance functions.
Dr. Vinay Gopal Nayak
Dr. Vinay Gopal Nayak, is an MSC and PhD in Chemistry. He is a pharmaceutical professional with technical background who has worked with Organisations such as Cipla, Lupin, Watson, Alembic and Emcure pharmaceuticals. He is specialised in the areas of Manufacturing, Quality, R&D, Compliance and Regulatory Affairs both for API and finished dosage form manufacturing. In a career span of 30 years he has provided leadership to the above organisations rise to become global leaders in their specialised segments.
Dr. Nayak has successfully handled USFDA and other international regulatory inspections with good leadership and sound technical knowledge.
In the past 10 years, he has worked in senior position of President Technical Operations at Watson, Alembic and Emcure. In these years, manufacturing operations at these organisations have been expanded exponentially. Apart from plant expansions and capacity enhancements, he has given the organisations very sound Quality systems which are capable of standing up to very tough regulatory inspections of recent years. As team player in each organisation he was capable of filing innovative ANDA and DMF products all these years through efficient Regulatory pathway.
His strength/ expertise involves selecting good teams, grooming them and meeting organisational expectations all these years.
The other area of expertise has been useful is to outsource key products in situations for capacity release in existing plants to make space for new approved products. He has also handled expansion projects involving designing GMP plants for finished dosage form as well as API.
Dr. Nayak is a member of Indian Pharmacopoeia, Examiner of Mumbai University for Masters and Ph.D students. He is a winner of many awards and recognitions and cited in Who's Who in the world. He is also an advisory board member of USP.
Dr. Vinay Gopal Nayak has joined Marksans in the capacity of Whole-time Director designated as Executive Director responsible for the entire technical Operations.
Marksans now has a leader to take the organisation to the next level.
Mr. A.S Mohanty
Mr. A.S Mohanty has joined Marksans Pharma Ltd As Executive Director at Mumbai. He has assumed the Sales, Marketing and Operations responsibilities of India and ROW.
His Last appointment was with Glenmark Pharmaceuticals Ltd Where he has served for 27 years out of total 40 years of service in Pharma industry. During this period Mr. Mohanty moved through Sales, Marketing, Operations, and International marketing. The last 9 Years was spent as Executive Director on the board of Glenmark Pharmaceuticals Ltd. With independent responsibility of India and ROW.
He is Post Graduate in Mathematics and has acquired several management certification courses from premium management institutions in India.
Mr. Sathish Kumar
MD – Marksans Pharma (UK) Ltd.
Mr. Sathish Kumar is Managing Director of Marksans Pharma (UK) Ltd. & manages Affairs of Bells & Sons (Druggists) Ltd and Relonchecm Ltd, both step down operating subsidiaries of Marksans Pharma (UK) Ltd. He has done masters in pharmacy and has over 20 years of experience in Pharma industry working across Production, Planning and inventory Management, Formulation development, Regulatory, Technical, Commercial, Sales and Business development.
Mr. David Mohammed
MD - Nova Pharmaceuticals Australasia Pty Ltd.
Mr. Mohammed held the positions of the Managing Director Australasia and Marketing Director Asia, Africa and Australasia at Valeant Pharmaceuticals for over 7 years, prior to Nova Pharmaceuticals.
Mr. Jitendra M Sharma
Chief Financial Officer
Mr. Sharma is a qualified chartered accountant and cost accountant with over 20 years experience in financial functions including treasury and forex management. He has expertise in the areas of costing, fund raising and internal control systems. He is a director in MPL’s subsidiaries, Marksans Pharma (UK) Ltd, Marksans Pharma Inc. (USA), Nova Pharmaceuticals, Australia and Relonchem, UK.